Full View

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

BD Shah, MR Bishop, OO Oluwole… - Blood, The Journal …, 2021 - ashpublications.org
Abstract ZUMA-3 is a phase 1/2 study evaluating KTE-X19, an autologous anti-CD19
chimeric antigen receptor (CAR) T-cell therapy, in adult relapsed/refractory (R/R) B-cell …
被引用次数：119 相关文章
[HTML] nih.gov

[HTML][HTML] KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

BD Shah, MR Bishop, OO Oluwole, AC Logan… - Blood, 2021 - ncbi.nlm.nih.gov
Abstract ZUMA-3 is a phase 1/2 study evaluating KTE-X19, an autologous anti-CD19
chimeric antigen receptor (CAR) T-cell therapy, in adult relapsed/refractory (R/R) B-cell …

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

BD Shah, MR Bishop, OO Oluwole, AC Logan… - Blood, 2021 - profiles.wustl.edu
Abstract ZUMA-3 is a phase 1/2 study evaluating KTE-X19, an autologous anti-CD19
chimeric antigen receptor (CAR) T-cell therapy, in adult relapsed/refractory (R/R) B-cell …

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

BD Shah, MR Bishop, OO Oluwole, AC Logan… - Blood, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> ZUMA-3 is a phase 1/2 study evaluating KTE-
X19, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult …

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.

BD Shah, MR Bishop, OO Oluwole, AC Logan… - Blood, 2021 - europepmc.org
Abstract ZUMA-3 is a phase 1/2 study evaluating KTE-X19, an autologous anti-CD19
chimeric antigen receptor (CAR) T-cell therapy, in adult relapsed/refractory (R/R) B-cell …

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

BD Shah, MR Bishop, OO Oluwole, AC Logan… - …, 2021 - pubmed.ncbi.nlm.nih.gov
ZUMA-3 is a phase 1/2 study evaluating KTE-X19, an autologous anti-CD19 chimeric
antigen receptor (CAR) T-cell therapy, in adult relapsed/refractory (R/R) B-cell acute …

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.

BD Shah, MR Bishop, OO Oluwole… - …, 2021 - digitalcommons.providence.org
Abstract ZUMA-3 is a phase 1/2 study evaluating KTE-X19, an autologous anti-CD19
chimeric antigen receptor (CAR) T-cell therapy, in adult relapsed/refractory (R/R) B-ALL. We …

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

BD Shah, MR Bishop, OO Oluwole… - …, 2021 - mdanderson.elsevierpure.com
Abstract ZUMA-3 is a phase 1/2 study evaluating KTE-X19, an autologous anti-CD19
chimeric antigen receptor (CAR) T-cell therapy, in adult relapsed/refractory (R/R) B-cell …
[HTML] sciencedirect.com

[HTML][HTML] KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

BD Shah, MR Bishop, OO Oluwole, AC Logan… - Blood, 2021 - Elsevier
Abstract ZUMA-3 is a phase 1/2 study evaluating KTE-X19, an autologous anti-CD19
chimeric antigen receptor (CAR) T-cell therapy, in adult relapsed/refractory (R/R) B-cell …

KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results

BD Shah, MR Bishop, OO Oluwole, AC Logan… - …, 2021 - providence.elsevierpure.com
Abstract ZUMA-3 is a phase 1/2 study evaluating KTE-X19, an autologous anti-CD19
chimeric antigen receptor (CAR) T-cell therapy, in adult relapsed/refractory (R/R) B-cell …